NCT00673049_2B: NCT00673049, figure 2B

NCT00673049_2BR Documentation

NCT00673049, figure 2B

Description

Kaplan-Meier digitized data from NCT00673049, figure 2B (PMID 25395283). A reported sample size of 583 for a primary endpoint of OS in lung cancer.

Usage

NCT00673049_2B

Format

A data frame of 583 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (control, figitumumab)

Source

Scagliotti GV, Bondarenko I, Blackhall F, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Ann Oncol 2015; 26: 497–504.

Examples

summary(NCT00673049_2B)

kmplot(NCT00673049_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.